27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
The socio-economic and health consequences of our ageing population are well documented, with older adults living in long-term care facilities amongst the frailest possessing specific and significant healthcare and social care needs. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Early-onset dementia (EOD) defines all dementia related conditions with an onset before the age of 65 years. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Sedative antidepressants are commonly used drugs in the treatment of insomnia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We have entered an era of a steep increase in the absolute and relative number of older people. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Insomnia is defined as difficulties of initiating and maintaining sleep, early awakening and poor subjective sleep quality despite adequate opportunity and circumstances for sleep with impairment of daytime performance. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Older adults who do not sleep well frequently have difficulty sustaining attention, display slower physical response times, and have memory issues that may contribute to depression or early dementia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
A growing number of studies in animal models have highlighted the link between sleep disorders and Alzheimer's disease (AD). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Sleep plays a critical role in homeostasis of the body and mind. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
42 common genes were identified between OSA and dementia which were primarily linked to the G-coupled protein receptor (GPCR) and olfactory pathways. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Sleep disorders are common in patients with Alzheimer's disease, and can even occur in patients with amnestic mild cognitive impairment, which appears before Alzheimer's disease. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Several causative factors are associated with hearing loss (HL) and brain disorders. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Presbycusis contributes to cognitive decline and Alzheimer's disease. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
With the increasing number of older adults around the world, the overall number of dementia cases is expected to rise dramatically in the next 40 years. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In recent years, there has been increasing research interest in the correlation between hearing impairment and cognitive decline, two conditions that have demonstrated a strong association. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
During ageing, the prevalence of Alzheimer's disease (AD) and of cardiovascular disease CVD) increases. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Bariatric surgery has been shown to improve cognition in patients with severe obesity. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The number of people suffering from dementia in the world is progressively increasing due to the expansion of the geriatric population in which this clinical condition is more frequent. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Women with chronic HIV infection (WWH) living in the United States, experience a disproportionately high rate of obesity compared to uninfected populations. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Neither medically amenable nor behavioral risk factors are uniformly better in Cuba than comparison countries. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Metabolic syndrome (MS) is a set of cardio-metabolic risk factors that includes central obesity, hyperglycemia, hypertension, and dyslipidemias. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is often comorbid with other pathologies. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Obesity is a global health problem with a broad set of comorbidities, such as malnutrition, metabolic syndrome, diabetes, systemic hypertension, heart failure, and kidney failure. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Evidence from epidemiological studies on the general population suggests that midlife cardiovascular disease (CVD) and/or metabolic syndrome (MetS) are associated with an increased risk of cognitive impairment and dementia later in life. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Post-stroke cognitive deficits and dementia Abstract. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cognitive reserve is characterized by a dissociation between cognitive level and brain structure, thereby reducing the impact of deteriorating brain structure on cognitive function. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →